Drugs / metenkefalin
metenkefalin
also known as
met-enkephalin · Opioid Growth Factor · [Met(5)]-enkephalin · Enkephalin-(5-l-methionine) · INNO-105 · Metencefalina · Metenkefaline · Methionine enkephalin · +4 more
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00706576 | Jun 2008 → Jul 2013 | hepatocellular carcinoma | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 1 | NCT00255333 | Nov 2005 → Mar 2007 | neoplasm | Innovive Pharmaceuticals | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00982696 | Feb 2008 → Nov 2011 | head and neck squamous cell carcinoma | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT00109941 | Oct 2003 → Sep 2007 | malignant pancreatic neoplasm | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04374032 | May → Oct 2020 | COVID-19 | Bosnalijek D.D | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03283397 | Mar 2019 → Jul 2023 | relapsing-remitting multiple sclerosis | Bosnalijek D.D | Terminated | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | metenkefalin | “10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.” NCT03283397 ↗ |
| Known as | [Met(5)]-enkephalin | “Opioid growth factor (OGF; [Met(5)]-enkephalin) is a natural peptide” PMID 20890374 ↗ Mar 2010 |
| Known as | Enkephalin-(5-l-methionine) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108291 ↗ |
| Known as | INNO-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00255333 ↗ |
| Known as | met-enkephalin | “All subjects treated with met-enkephalin (also called OGF) 250 ug/kg iv weekly” NCT00109941 ↗ |
| Known as | Metencefalina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108291 ↗ |
| Known as | Metenkefaline | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108291 ↗ |
| Known as | Methionine enkephalin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108291 ↗ |
| Known as | NSC-374896 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108291 ↗ |
| Known as | OGF | “All subjects treated with met-enkephalin (also called OGF) 250 ug/kg iv weekly” NCT00109941 ↗ |
| Known as | Opioid Growth Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00706576 ↗ |
| Known as | Sh-pentapeptide-19 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108291 ↗ |
| Known as | Tyr-gly-gly-phe-met | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108291 ↗ |
| Action | Inhibit | “Opioid Growth Factor (OGF) inhibits the growth of a number of cancer lines in vitro by a receptor-mediated mechanism.” NCT00706576 ↗ |
| Modality | Peptide | “Opioid growth factor (OGF; [Met(5)]-enkephalin) is a natural peptide” PMID 20890374 ↗ Mar 2010 |
| Route | Intravenous | “Weekly Intravenous INNO-105” NCT00255333 ↗ |
| Target | OGFR | “OGF interacts with the OGFr receptor zeta (OGFr) to influence growth.” NCT00706576 ↗ |